--- title: "Contineum Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285259653.md" datetime: "2026-05-05T20:18:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285259653.md) - [en](https://longbridge.com/en/news/285259653.md) - [zh-HK](https://longbridge.com/zh-HK/news/285259653.md) --- # Contineum Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.39. EBIT: As of FY2026 Q1, the actual value is USD -19.41 M. Contineum Therapeutics, Inc. reported its first-quarter 2026 financial results, highlighting key financial and operational metrics . #### Cash and Liquidity As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $246.3 million . Cash and cash equivalents were $20.158 million, a decrease from $75.603 million as of December 31, 2025 . Marketable securities increased to $226.170 million as of March 31, 2026, from $187.293 million as of December 31, 2025 . #### Operating Expenses Research and development expenses for the first quarter of 2026 were $11.6 million, representing a 15 percent decrease from $13.712 million in the first quarter of 2025 . This decrease was primarily due to the completion of the PIPE-307 VISTA trial and lower costs for the PIPE-791 PET trial, partially offset by increased expenses for the PIPE-791 IPF program and higher employee-related costs . General and administrative expenses rose by 20 percent to $5.3 million in the first quarter of 2026, compared to $4.398 million in the first quarter of 2025, mainly driven by higher stock-based compensation and employee-related costs . Total operating expenses for the quarter were $16.904 million, down from $18.110 million in the prior year’s first quarter . #### Net Loss and Comprehensive Loss Net loss for the three months ended March 31, 2026, was -$14.5 million, an improvement from a net loss of -$16.0 million for the first quarter of 2025 . Interest income increased to $2.505 million in Q1 2026 from $2.250 million in Q1 2025 . Other expense, net, was -$0.057 million compared to -$0.130 million in the same periods, respectively . Total other income, net, was $2.448 million in Q1 2026, up from $2.120 million in Q1 2025 . Comprehensive loss for the quarter was -$14.969 million, compared to -$15.891 million in the first quarter of 2025 . Net loss per share, basic and diluted, was -$0.39 for Q1 2026, compared to -$0.62 for Q1 2025 . #### Balance Sheet Highlights Total current assets were $252.964 million as of March 31, 2026, decreasing from $267.917 million as of December 31, 2025 . Total assets were $261.349 million as of March 31, 2026, down from $276.642 million as of December 31, 2025 . Total current liabilities decreased to $6.657 million from $9.744 million, and total liabilities decreased to $11.308 million from $15.653 million over the same period . Total stockholders’ equity was $250.041 million as of March 31, 2026, compared to $260.989 million as of December 31, 2025 . #### Operational Milestones Contineum Therapeutics, Inc. reported positive topline data on April 30, 2026, from its exploratory Phase 1b trial of PIPE-791 for chronic osteoarthritis pain or chronic low back pain, meeting its primary safety and tolerability objective . Patients treated with PIPE-791 showed numerically greater pain improvements from baseline compared to the placebo arm . The company initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial for PIPE-791 in idiopathic pulmonary fibrosis (IPF), in the first quarter of 2026 . Additionally, Johnson & Johnson began recruiting for a Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in December 2024, with an estimated completion in June 2026 . #### Outlook Contineum Therapeutics, Inc. believes its cash resources are sufficient to fund planned operations through mid-2029 . This projected cash runway extends approximately one year past the estimated completion of its IPF trial . The company maintains a disciplined approach to capital allocation, prioritizing its lead clinical indication while considering other programs . ### Related Stocks - [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md) ## Related News & Research - [Contineum Therapeutics CEO Carmine Stengone sells 10,000 common shares for $160,080](https://longbridge.com/en/news/291469248.md) - [Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 556,791 common shares](https://longbridge.com/en/news/291593149.md) - [Contineum Therapeutics updates corporate presentation; highlights PIPE-791 progress, cash runway through mid-2029](https://longbridge.com/en/news/292528102.md) - [Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)](https://longbridge.com/en/news/285874282.md) - [Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference](https://longbridge.com/en/news/279135975.md)